Peramivir: Evidence to support the use of the first approved intravenous therapy for influenza

Jeremy Katzen, Michael G. Ison*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Peramivir, an intravenous neuraminidase inhibitor, was first available in clinical practice during the 2009 A/H1N1 pandemic under an Emergency Use Authorization by the US FDA. As the lone intravenous neuraminidase inhibitor available and with a novel structure compared with the available neuraminidase inhibitors, it was offered as an alternative to patients not responding to existing therapy or without enteric access. Since the expiration of the Emergency Use Authorization, peramivir has undergone multiple clinical trials for the treatment of both uncomplicated influenza infection in the ambulatory setting and complicated influenza infection in the hospitalized setting. With the recent FDA approval of single-dose therapy for uncomplicated influenza infection, we will review the preclinical and clinical data, to date, on peramivir.

Original languageEnglish (US)
Pages (from-to)937-948
Number of pages12
JournalFuture Virology
Issue number8
StatePublished - Aug 1 2015


  • BCX-1812
  • RWJ-270201
  • antiviral therapy
  • influenza
  • neuraminidase inhibitors
  • peramivir

ASJC Scopus subject areas

  • Virology


Dive into the research topics of 'Peramivir: Evidence to support the use of the first approved intravenous therapy for influenza'. Together they form a unique fingerprint.

Cite this